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CHARACTERIZATION OF OUTCOMES AFTER SECONDARY SYSTEMIC
TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
Inamoto, Y., Storer, B.E., Lee, S.J., Carpenter, P.A., Flowers, M.E.D.,
Martin, P.J. Fred Hutchinson Cancer Research Center, Seattle, WA
Background:Nearly 50% of patients with chronic graft-versus-host
disease (GVHD) require secondary systemic treatment to control
the disease. Outcomes after secondary treatment and the associated
prognostic factors have not been examined well. This retrospective
study had 3 goals; (1) to establish a benchmark that could be used
to evaluate the efficacy of secondary treatment in future trials, (2)
to elucidate prognostic factors associated with outcomes, and (3) to
test the hypothesis that a composite of response and steroid dose
at 6 months correlates with long-term outcomes, similar to results
observed in a trial of primary treatment for chronic GVHD
(BBMT 2011;17:124).
Methods: The study included 289 consecutive relapse-free patients
who had high-intensity conditioning and required secondary treat-
ment for chronic GVHD due to worsening or persistence of
GVHD. Failure was defined as third-line systemic treatment or
death, with recurrentmalignancy considered a competing risk. Plate-
let count, serum bilirubin concentration and prednisone dose were
assessed at start of secondary treatment. Response was assessed at
6 months among 174 patients without prior failure or relapse, and
was defined as complete response in any organ, prednisone dose
\0.25 mg/kg, or the combination. Cox regressions were used to
evaluate potential risk factors for failure at the beginning of second-
ary treatment, and to evaluate the risk of subsequent failure associ-
ated with the 3 response definitions at 6 months.
Results:Median age of the patients was 44 (1-70) years. The single
agents most commonly used for secondary treatment includedMMF
(n 5 83), tacrolimus (n 5 73) and sirolimus (n 5 51); 16 received
multiple new agents at start of secondary treatment. The cumulative
incidence of failure was 48% (95% CI, 42-53%) at 1 year. Cox
models revealed that the risk of failure was increased in patients
treated with multiple agents and in those with thrombocytopenia,
hyperbilirubinemia or oral involvement at the beginning of second-
ary treatment.None of the 3 response definitions showed strong cor-
relation with the risk of subsequent failure (Table).
Table. Correlation of response after secondary treatment
with subsequent failure
CumulativeResponse definition
Response at
6 months Nincidence
of failure* PCR in any organ Y 103 37% 0.66
N 65 43%Prednisone dose
<0.25 mg/kg/dayY 104 35% 0.05N 66 47%
CR in any organ
and prednisone
dose <0.25 mg/kg/dayY 64 34% 0.25N 103 43%*At 2 years after the beginning of secondary treatment.
Conclusion: Secondary treatment for chronic GVHD is associated
with a 48% failure rate at one year, with failure predicted by throm-
bocytopenia, hyperbilirubinemia or oral involvement. Unlike the re-
sults reported for primary treatment, a composite of response and
steroid dose would not perform well as a surrogate endpoint in sec-
ondary treatment studies.
53
EXTRACORPOREAL PHOTOPHERESIS: EFFECTIVE THERAPY FOR STE-
ROID DEPENDENT AND REFRACTORY ACUTE GRAFT-VERSUS-HOST DIS-
EASE
Jacobs, R.W.1, Jagasia, M.H.2, Savani, B.N.2, Neff, A.T.2,
Engelhardt, B.G.2, Goodman, S.2, Greer, J.P.2, Proctor, K.2,
Schuening, F.3, Russell, N.H.4, Das-Gupta, E.4 1Vanderbilt University
Medical Center, Nashville, TN; 2Vanderbilt University Medical Center,Nashville, TN; 3St. Louis University, St. Louis, MO; 4Nottingham Uni-
versity Hospital, Nottingham, United Kingdom
Outcome of patients (pts) with steroid refractory (SR) acute graft-
versus-host disease (aGVHD) remains poor. We studied the efficacy
and outcome of extracorporeal photopheresis (ECP) used as salvage
therapy for pts with SR (progression of aGVHD after 3 days or no
response after 7 days of $ 1mg/kg of prednisone equivalent) or ste-
roid dependent (SD) aGVHD (recurrence of aGVHDduring steroid
taper) at Vanderbilt University, USA (n5 29) and Nottingham, UK
(n5 23). Responses to ECP were determined at completion of ECP.
Results: 52 pts were treated for SD (29%) or SR (63%) grade 2-4
aGVHD. Indication for ECP was missing for 5 pts. Grade 3-4
aGVHD was present at onset in 29 (57%) pts with 3 organ involve-
ment in 9 (17%) pts.Median duration of ECPwas 55 days. At the end
of ECP treatment, grade 3-4 aGVHD was present in 17 pts (33%).
The median steroid dose at end of ECP in responders and non-re-
sponders was 0.15 mg/kg (range, 0-0.75) and 2 mg/kg (range,
0.15-2.3) (P\0.001). Donor type, stem cell source, GVHD prophy-
laxis, aGVHDgrade at onset, and organ specific stage did not impact
response. ECP response was superior for aGVHD developing after
ablative regimen (76%) compared with other regimens (48%) (P 5
0.05). Pts with response at 7 days after initial steroid treatment and
subsequent steroid dependent aGVHD had a better response with
ECP (80% vs. 50%, P 5 0.042). In logistic regression analyses, ad-
justed for regimen intensity, response after 7 days of initial steroid
therapy showed a trend for predicting ECP response (OR 5 4.22,
95% CI 0.95-18.7, P 5 0.058). 2-yr overall survival in all patients
and in ECP responders was 42% and 65%, respectively. Median sur-
vival after ECP onset was superior for pts receiving an ablative com-
pared to other regimens (not reached vs. 44 days, P 5 0.05), and
grade 1-2 aGVHD compared to grade 3-4 aGVHD at onset (not
reached vs. 79 days, P5 0.028). SD or SR status did not impact sur-
vival. Pts with ECP response had a superior survival (measured from
end of ECP) compared to non-responders (median survival, not
reached vs. 14 days, P\0.001). In Cox proportional analyses, re-
sponse to ECP was an independent predictor of survival (HR
0.091, 95% CI 0.034-0.263, P\0.001), adjusted for regimen inten-
sity and aGVHD grade at onset.
Conclusion: ECP is an effective steroid-sparing salvage therapy for
pts with SD/SR aGVHD. It is reasonable to undertake a prospective
randomized study of ECP versus other agents, in pts with SD/SR
aGVHD.
Table. GVHD, ECP and Response Characteristics of Patients
(N 5 52)
Variable N (%)aGVHD (steroid dependent/refractory)
CharacteristicsAfter first transplant 44 (85)
After second transplant 1 (2)
After donor lymphocyte infusion 7 (13)
Skin involvement (stage 3 or 4) at ECP onset 28 (37)
Gastrointestinal involvement at ECP onset 15 (29)
Liver involvement at ECP onset 9 (18)
Steroid therapy for aGVHD
Duration of steroids prior to ECP, median, days
(range)
18 (10-91)Steroid dose 1 mg/kg 24 (46)
Steroid dose 2 mg/kg 26 (50)
ECP Characteristics
Time to onset of ECP, median, days (range) 59 (12-99)
ECP treatments, median (range) 12 (2-45)
ECP response
Complete response 26 (50)
Partial response 6 (12)
Skin involvement (stage 3 or 4) at end of ECP 4 (8)
Gastrointestinal involvement at end of ECP 10 (20)
Liver involvement at end of ECP 10 (20)
Survival Characteristics
Follow-up, median, days (range) 309 (12-1657)
Alive/Deceased 24 (46)/28 (54)
Median survival (measured from ECP onset), days
(95% CI)
442 (0-993)
